Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | SAT1 | P21673 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL128359 | 1.00 | ANPEP (0.54) | ANPEPMMP2MMP1MMP3MMP9 | |
| Phosphoric Acid SCHEMBL28426124 | 0.97 | ANPEP (0.52) | ANPEPMMP2MMP1MMP3MMP9 | |
| Phosphoric Acid SCHEMBL27548473 | 0.89 | ANPEP (0.47) | ANPEPMMP2MMP1MMP3MMP9 | |
| Phosphoric Acid SCHEMBL14782467 | 0.87 | ANPEP (0.50) | ANPEPMMP2MMP1MMP3MMP9 | |
| SCHEMBL5595395 | 0.86 | S1PR2 (0.59) | ANPEPMMP2MMP1MMP3MMP9 | |
| Hydrochloric Acid SCHEMBL5985877 | 0.84 | S1PR2 (0.57) | ANPEPMMP2MMP1MMP3MMP9 | |
| Phosphoric Acid SCHEMBL2776516 | 0.82 | S1PR2 (0.61) | ANPEPMMP2MMP1S1PR2S1PR1 | |
| Phosphoric Acid SCHEMBL2776513 | 0.82 | S1PR2 (0.61) | ANPEPMMP2MMP1S1PR2S1PR1 | |
| SCHEMBL16713982 | 0.82 | ANPEP (0.45) | ANPEPMMP2MMP1MMP3MMP9 | |
| SCHEMBL11504880 | 0.80 | S1PR2 (0.43) | ANPEPMMP2MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | WILLIAM M YARBROUGH FOUND (US) | 2026-02-26 | — | — | US | claimed |
| US-12310939-B2 | Method for treating rheumatoid arthritis | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2025-05-22 | — | — | US | claimed |
| CN-119771345-A | Pyrophospholybdate adsorption material for extracting rubidium and cesium from salt lake brine, and preparation method and application thereof | 江苏苏青水处理工程集团有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119776078-A | Cleaning composition | 宝洁公司 | 2025-04-08 | — | — | CN | claimed |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-03-04 | — | — | US | claimed |
| US-20250011688-A1 | COMPOSITION | PROCTER & GAMBLE (US) | 2025-01-09 | — | — | US | claimed |
| US-12178795-B2 | Method for treating metastatic prostate cancer | THE WILLIAM YARBROUGH FOUNDATION (US) | 2024-12-31 | — | — | US | claimed |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-10-26 | — | — | US | claimed |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-24 | — | — | US | claimed |
| US-6531444-B1 | Fragrant burst upon ironing; hydrophobic candelilla wax/silicon copolymer; cationic charge boosters and fabric softeners | SALVONA, LLC | 2003-03-11 | — | — | US | claimed |
| US-20020122781-A1 | Cosmetic compositions containing heteropolymers and oil-soluble cationic surfactants and methods of using same | PINZON CARLOS O (US) | 2002-09-05 | — | — | US | claimed |
| WO-2002047620-A2 | COMPOSITIONS CONTAINING HETEROPOLYMERS AND METHODS OF USING SAME | L'OREAL SA (FR) | 2002-06-20 | — | — | WO | claimed |
| WO-2002047658-A2 | COSMETIC COMPOSITIONS CONTAINING HETEROPOLYMERS AND OIL-SOLUBLE CATIONIC SURFACTANTS AND METHODS OF USING SAME | L'OREAL SA (FR) | 2002-06-20 | — | — | WO | claimed |
| WO-2002038713-A1 | A CONTROLLED DELIVERY SYSTEM FOR FABRIC CARE PRODUCTS | SALVONA, L.L.C. (US) | 2002-05-16 | — | — | WO | claimed |
| US-6147038-A | MIXTURE CONTAINING DIALKYLQUATERNARY AMINE SALT; HAIR CONDITIONER | DOW CORNING CORPORATION (US) | 2000-11-14 | — | — | US | claimed |
| EP-0705864-B1 | Method of emulsion polymerization | DOW CORNING (US) | 2000-03-01 | — | — | EP | claimed |
| EP-0955288-A2 | Dialkylquat and trialkylquat benzoate and salicylate salts | WITCO CORPORATION (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0705864-A1 | Method of emulsion polymerization | DOW CORNING CORPORATION (US) | 1996-04-10 | — | — | EP | claimed |
| US-5504149-A | MIXING WATER, CYCLIC SILOXANE, NONIONIC SURFACTANT, CATIONIC SURFACTANT, ADDING SILANOLATE POLYMERIZATION INITIATOR, HEATING, AGITATING, POLYMERIZING TO SILICONE EMULSION | DOW CORNING CORPORATION (US) | 1996-04-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020122781-A1 | Cosmetic compositions containing heteropolymers and oil-soluble cationic surfactants and methods of using same | SYMPK, CUTA, LSS | ANPEP 4434/4885MMP2 4138/4885MMP1 4206/4885 |
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | ALK, C9, MSR1 | ANPEP 4417/4885MMP2 1097/4885MMP1 963/4885 |
| US-12178795-B2 | Method for treating metastatic prostate cancer | BPHL, KLK3, ACP3 | ANPEP 916/4885MMP2 133/4885MMP1 136/4885 |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | CFTR, TST, ICMT | ANPEP 1091/4885MMP2 1142/4885MMP1 679/4885 |
| US-12310939-B2 | Method for treating rheumatoid arthritis | MIF, TNF, MMP12 | ANPEP 511/4885MMP2 19/4885MMP1 12/4885 |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, TMSB10, NHERF1 | ANPEP 2747/4885MMP2 376/4885MMP1 25/4885 |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | MIF, TNF, MMP12 | ANPEP 717/4885MMP2 50/4885MMP1 25/4885 |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | CFTR, TST, ICMT | ANPEP 1091/4885MMP2 1142/4885MMP1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.